Zacks Research Expects Stronger Earnings for Gilead Sciences

Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) - Equities researchers at Zacks Research raised their Q2 2025 earnings per share estimates for shares of Gilead Sciences in a research note issued on Thursday, January 16th. Zacks Research analyst E. Bagri now forecasts that the biopharmaceutical company will post earnings of $1.75 per share for the quarter, up from their previous forecast of $1.72. The consensus estimate for Gilead Sciences' current full-year earnings is $4.36 per share. Zacks Research also issued estimates for Gilead Sciences' Q4 2025 earnings at $1.86 EPS, FY2025 earnings at $7.12 EPS, Q3 2026 earnings at $2.19 EPS, Q4 2026 earnings at $2.03 EPS and FY2026 earnings at $7.55 EPS.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last issued its quarterly earnings data on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share for the quarter, beating the consensus estimate of $1.58 by $0.44. Gilead Sciences had a net margin of 0.45% and a return on equity of 29.00%. The firm had revenue of $7.55 billion for the quarter, compared to analyst estimates of $7.01 billion. During the same quarter last year, the firm earned $2.29 earnings per share. The company's revenue for the quarter was up 7.0% on a year-over-year basis.

Several other equities analysts have also recently weighed in on GILD. Leerink Partnrs raised Gilead Sciences from a "hold" rating to a "strong-buy" rating in a research report on Monday, October 21st. Needham & Company LLC reiterated a "hold" rating on shares of Gilead Sciences in a report on Thursday, November 7th. Oppenheimer increased their price objective on Gilead Sciences from $105.00 to $115.00 and gave the company an "outperform" rating in a research report on Tuesday, December 10th. Bank of America reaffirmed a "buy" rating and set a $109.00 target price on shares of Gilead Sciences in a research report on Tuesday, December 10th. Finally, UBS Group increased their price target on shares of Gilead Sciences from $70.00 to $96.00 and gave the company a "neutral" rating in a report on Thursday, November 21st. Eleven research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and four have given a strong buy rating to the company. According to data from MarketBeat, Gilead Sciences has a consensus rating of "Moderate Buy" and a consensus price target of $97.96.

Gilead Sciences Stock Performance

Shares of GILD stock traded up $0.19 during trading on Monday, reaching $91.84. The company had a trading volume of 6,852,085 shares, compared to its average volume of 5,370,915. The firm's 50 day simple moving average is $91.75 and its two-hundred day simple moving average is $84.20. Gilead Sciences has a one year low of $62.07 and a one year high of $98.90. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.26 and a quick ratio of 1.10. The company has a market capitalization of $114.46 billion, a PE ratio of 1,020.44, a PEG ratio of 1.27 and a beta of 0.18.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the business. nVerses Capital LLC bought a new stake in shares of Gilead Sciences during the third quarter worth approximately $25,000. Decker Retirement Planning Inc. bought a new stake in Gilead Sciences in the 4th quarter valued at $29,000. Valued Wealth Advisors LLC grew its holdings in Gilead Sciences by 101.9% in the 3rd quarter. Valued Wealth Advisors LLC now owns 319 shares of the biopharmaceutical company's stock valued at $27,000 after buying an additional 161 shares in the last quarter. Strategic Investment Solutions Inc. IL bought a new position in Gilead Sciences during the 2nd quarter worth $33,000. Finally, Friedenthal Financial acquired a new stake in shares of Gilead Sciences during the third quarter worth $50,000. 83.67% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Gilead Sciences

In related news, CFO Andrew D. Dickinson sold 2,500 shares of the stock in a transaction that occurred on Wednesday, January 15th. The stock was sold at an average price of $91.35, for a total transaction of $228,375.00. Following the completion of the transaction, the chief financial officer now directly owns 129,873 shares of the company's stock, valued at approximately $11,863,898.55. This represents a 1.89 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Merdad Parsey sold 25,590 shares of the firm's stock in a transaction on Wednesday, November 6th. The shares were sold at an average price of $91.50, for a total transaction of $2,341,485.00. Following the completion of the transaction, the insider now directly owns 99,599 shares of the company's stock, valued at $9,113,308.50. This represents a 20.44 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 456,234 shares of company stock valued at $42,130,461 over the last 90 days. 0.29% of the stock is owned by company insiders.

Gilead Sciences Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Monday, December 30th. Shareholders of record on Friday, December 13th were issued a $0.77 dividend. The ex-dividend date of this dividend was Friday, December 13th. This represents a $3.08 annualized dividend and a dividend yield of 3.35%. Gilead Sciences's dividend payout ratio (DPR) is currently 3,422.22%.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.